Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma — Josep M. Llovet (2025) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma
Shared by
Josep M. Llovet
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma
Article
2025
en
Authors
Josep M. Llovet
Translational Research In Hepatic Oncology
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2008
Novel advancements in the management of hepatocellular carcinoma in 2008
Josep M. Llovet
,
Jordi Bruix
Journal of Hepatology
Article
2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Tomi Jun
,
Umut Özbek
,
Sirish Dharmapuri
,
Camille Hardy-Abeloos
,
Huili Zhu
,
Jung-Yi Lin
,
Nicola Personeni
,
Tiziana Pressiani
,
Naoshi Nishida
,
Pei-Chang Lee
,
Chieh-Ju Lee
,
Hannah Hildebrand
,
Neil Nimkar
,
Sonal Paul
,
Petros Fessas
,
Muntaha Naeem
,
Dominik Bettinger
,
Uqba Khan
,
Anwaar Saeed
,
Yi‐Hsiang Huang
,
Masatoshi Kudo
,
Lorenza Rimassa
,
Thomas U. Marron
,
David J. Pinato
,
Celina Ang
Article
2023
Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma
Masahiro Morita
,
Naoshi Nishida
,
Tomoko Aoki
,
Hirokazu Chishina
,
Masahiro Takita
,
Hiroshi Ida
,
Satoru Hagiwara
,
Yasunori Minami
,
Kazuomi Ueshima
,
Masatoshi Kudo
Article
2023
Advances in Immunotherapy for Hepatocellular Carcinoma
Satoru Hagiwara
,
Naoshi Nishida
,
Masatoshi Kudo
Editorial Material
2018
Combination Cancer Immunotherapy in Hepatocellular Carcinoma
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.